Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) has made a 28.71% comeback from a 12-month low price of $1.01. It was seen 4.84% higher, changing the price to $1.3, when the closing bell rang on 3/14/2019. At a recent session, the prices were hovering between $1.25 and $1.3. This company shares are 407.69% off its target price of $6.6 and the current market capitalization stands at $77.25M. The recent change has given its price a 2.77% lead over SMA 50 and -71.05% deficit over its 52-week high. The stock witnessed 8.33% gains, -19.25% declines and -59.63% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found TTPH’s volatility during a week at 5.45% and during a month it has been found around 6.69%.

Tetraphase Pharmaceuticals, Inc. (TTPH) Top Holders

Institutional investors currently hold around $29 million or 45.4% in TTPH stock. Look at its top three institutional owners: Blackrock Inc. owns $4.75 million in Tetraphase Pharmaceuticals, Inc., which represents roughly 6.15% of the company’s market cap and approximately 16.38% of the institutional ownership. Similar statistics are true for the second largest owner, Dimensional Fund Advisors Lp, which owns 2,516,272 shares of the stock are valued at $3.12 million. The third largest holder is Renaissance Technologies Llc, which currently holds $3.01 million worth of this stock and that ownership represents nearly 3.9% of its market capitalization.

Tetraphase Pharmaceuticals, Inc. 13F Filings

At the end of December reporting period, 39 institutional holders increased their position in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) by some 4,660,809 shares, 36 decreased positions by 4,023,756 and 24 held positions by 14,970,772. That puts total institutional holdings at 23,655,337 shares, according to SEC filings. The stock grabbed 8 new institutional investments totaling 716,602 shares while 12 institutional investors sold out their entire positions totaling 741,362 shares.

Tetraphase Pharmaceuticals, Inc. (TTPH) Analyst Guide

Several analysts have released their opinion on Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), with 1 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 5 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2 average brokerage recommendation [T1].